Louisiana's 2026 Healthcare Legislation Advances Major Changes
Key Takeaways
- Louisiana's 2026 healthcare legislation included Act 572, which restructures utilization management in Medicaid by requiring managed care organizations to respond to standard service authorization requests within seven calendar days.
- Louisiana will require Medicaid coverage of FDA-approved weight loss medications when medically necessary and prescribed by a licensed provider, though implementation depends on state funding.
- New pharmacy benefit manager regulations prohibit PBMs from changing consumer out-of-pocket costs for prescription drugs and require PBMs to cover all professional dispensing fees without passing costs to health plans or pharmacies.
- Louisiana established a prescription drug affordability board to identify high-cost drugs annually and recommend cost-reduction strategies to the legislature, supported by new manufacturer price reporting requirements.
- Health insurers must now place generic equivalents and biosimilars on formularies with better cost-sharing than brand-name drugs when the alternatives have lower wholesale costs, and cannot impose more burdensome prior authorization on the lower-cost options.
- Jump to frequently asked questions ↓
Overview of Louisiana's 2026 Legislative Session and Health Care Focus
Louisiana's 2026 regular legislative session adjourned June 1 after nearly three months of work. Healthcare was a dominant theme in the session's closing weeks, with lawmakers advancing a multitude of significant and interconnected bills targeting Medicaid coverage and utilization management practices, drug pricing and formulary rules, and pharmacy benefit manager (PBM) practices.
How Did Louisiana Change Medicaid Coverage and Utilization Management in 2026?
Medicaid Utilization Management Reforms
HB 915 was signed into law as Act 572, and it restructures Medicaid's utilization management processes. The bill requires Medicaid managed care organizations (MCOs) to act as expeditiously as the enrollee's health condition requires. Among other timelines outlined in the bill, standard service authorization requests must be provided within seven calendar days.
Coverage of FDA-Approved Weight Loss Medications
SB 433 was enrolled and requires the Medicaid program to cover FDA-approved weight loss medications, if they are medically necessary, prescribed by a licensed health care provider, and meet criteria established by the Louisiana Department of Health. Implementation is contingent on appropriation.
Utilization Management
Utilization management is a set of processes used by health insurers and managed care organizations to evaluate the medical necessity, appropriateness, and efficiency of healthcare services before, during, or after they are provided. This includes prior authorization requirements and service authorization requests.
Pharmacy Benefit Manager (PBM)
A pharmacy benefit manager is a third-party administrator that manages prescription drug benefits on behalf of health insurers, employers, and government programs. PBMs negotiate drug prices with manufacturers, process prescription claims, and determine which drugs are covered on insurance formularies.
Biosimilar
A biosimilar is a biological product that is highly similar to an already FDA-approved reference biological product (often called a brand-name biologic) with no clinically meaningful differences in safety, purity, or potency. Biosimilars typically cost less than their reference products.
Wholesale Acquisition Cost
Wholesale acquisition cost is the manufacturer's list price for a drug to wholesalers or direct purchasers in the United States, not including discounts or rebates. It serves as a benchmark for comparing drug prices and determining formulary placement.
Step Therapy
Step therapy is a utilization management practice that requires patients to try one or more lower-cost medications before their insurance will cover a more expensive alternative. Patients must "fail" the first-line treatment before progressing to the next step.
Upper Payment Limit
An upper payment limit is a maximum price that can be charged or reimbursed for a prescription drug within a state or health system. Some prescription drug affordability boards have authority to set these limits, though Louisiana's board does not.
What New Rules Affect Drug Pricing, Formularies, and PBM Practices in Louisiana?
Formulary Placement and Cost-Sharing for Generics and Biosimilars
HB 870 requires that when a health insurance issuer covers a brand-name reference drug and a generic equivalent or biosimilar enters the market with a lower wholesale acquisition cost, the insurer must place that lower-cost product on the formulary with more favorable cost-sharing than the reference product. The bill also prohibits insurers from imposing prior authorization and step therapy processes that would make accessing the generic or biosimilar more burdensome than accessing the brand.
Restrictions on PBM Cost-Sharing and Dispensing Fees
HB 1236 prohibits PBMs from changing or amending the out-of-pocket cost-share that a consumer pays for a prescription drug. Among other elements, it requires PBMs to bear all costs associated with professional dispensing fees and prohibits those costs from being passed along to health plans, plan members, pharmacies, or pharmacists.
Prescription Drug Affordability Board and Drug Price Reporting Requirements
SB 401 was enrolled. It establishes a Prescription Drug Affordability Board (PDAB) for the state. While the PDAB does not have an upper payment limit or other price control authority, it is tasked with identifying an annual list of high-cost drugs in the state and submitting recommendations to the legislature to lower prescription drug costs before the start of the session. To help make the list, the bill imposes new drug price reporting requirements on drug manufacturers.
Track Health Care Policy
The ever-evolving state health policy landscape will continue to influence how health care organizations make business decisions. MultiState's team pulls from decades of expertise to help you effectively navigate and engage. MultiState's team understands the issues, knows the key players and organizations, and we harness that expertise to help our clients effectively navigate and engage on their policy priorities. We offer customized strategic solutions to help you develop and execute a proactive multistate agenda focused on your company's goals. Learn more about our Health Care Policy Practice.
What does Louisiana HB 915 require for Medicaid prior authorization timelines?
Louisiana HB 915, signed into law as Act 572, requires Medicaid managed care organizations to process standard service authorization requests within seven calendar days. The law mandates that MCOs act as expeditiously as the enrollee's health condition requires when handling utilization management processes.
Does Louisiana Medicaid cover weight loss medications under SB 433?
Louisiana SB 433 requires the Medicaid program to cover FDA-approved weight loss medications if they are medically necessary, prescribed by a licensed health care provider, and meet criteria established by the Louisiana Department of Health. However, implementation is contingent on appropriation.
How does Louisiana HB 870 affect generic drug and biosimilar coverage?
Louisiana HB 870 requires health insurers to place generic equivalents or biosimilars on formularies with more favorable cost-sharing than brand-name reference drugs when the generic or biosimilar has a lower wholesale acquisition cost. The law also prohibits insurers from imposing prior authorization or step therapy requirements that make accessing the generic or biosimilar more burdensome than accessing the brand-name drug.
What does Louisiana HB 1236 prohibit pharmacy benefit managers from doing?
Louisiana HB 1236 prohibits PBMs from changing or amending the out-of-pocket cost-share that consumers pay for prescription drugs. The law requires PBMs to bear all costs associated with professional dispensing fees and prohibits those costs from being passed to health plans, plan members, pharmacies, or pharmacists.
Does Louisiana's Prescription Drug Affordability Board have authority to set drug price limits?
Louisiana SB 401 establishes a Prescription Drug Affordability Board that does not have upper payment limit or other price control authority. The board is tasked with identifying an annual list of high-cost drugs and submitting recommendations to the legislature to lower prescription drug costs, supported by new drug price reporting requirements imposed on manufacturers.